Rezolute (RZLT) Other Non-Current Assets (2012 - 2026)
Rezolute recorded quarterly Other Non-Current Assets of $2.4 million in Q1 2026, up 1.71% quarter-over-quarter from $2.4 million in Q4 2025, and down 16.48% year-over-year from $2.9 million in Q1 2025.
Rezolute's Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 16.48% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 16.48% YoY), while the FY2025 annual figure was $2.9 million, up 59.14% from the prior year.
- Other Non-Current Assets came in at $2.4 million for Q1 2026 at Rezolute, up from $2.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.0 million in Q1 2022 to a low of $148000.0 in Q2 2022.
- A 5-year average of $1.7 million and a median of $1.8 million in 2024 frame the typical range for Other Non-Current Assets.
- On a YoY basis, Other Non-Current Assets climbed as much as 41566.67% in 2022 and fell as far as 97.04% in 2022.
- Rezolute's Other Non-Current Assets stood at $148000.0 in 2022, then surged by 213.51% to $464000.0 in 2023, then jumped by 510.34% to $2.8 million in 2024, then fell by 15.18% to $2.4 million in 2025, then increased by 1.71% to $2.4 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.4 million, $2.4 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 2.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.44 Mn |
| Dec 31, 2025 | 2.40 Mn |
| Sep 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.93 Mn |
| Mar 31, 2025 | 2.93 Mn |
| Dec 31, 2024 | 2.83 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.84 Mn |
| Dec 31, 2023 | 464,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 148,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Dec 31, 2022 | 148,000.00 |
| Sep 30, 2022 | 148,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 5.00 Mn |
| Sep 30, 2021 | 72,000.00 |
| Jun 30, 2021 | 191,000.00 |
| Mar 31, 2021 | 12,000.00 |
| Dec 31, 2020 | 122,000.00 |
| Sep 30, 2020 | 129,000.00 |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 35,000.00 |
| Dec 31, 2019 | 1.53 Mn |
| Sep 30, 2019 | 35,000.00 |
| Jun 30, 2019 | 35,000.00 |
| Jun 30, 2018 | 56,841.00 |
| Mar 31, 2018 | 56,841.00 |
| Dec 31, 2017 | 244,341.00 |
| Sep 30, 2017 | 244,341.00 |
| Jun 30, 2017 | 244,341.00 |
| Mar 31, 2017 | 375,000.00 |
| Dec 31, 2016 | 375,000.00 |
| Sep 30, 2016 | 375,000.00 |
| Jun 30, 2016 | 375,000.00 |
| Dec 31, 2015 | 562,500.00 |
| Sep 30, 2015 | 450,280.00 |
| Jun 30, 2015 | 450,167.00 |
| Mar 31, 2015 | 450,055.00 |
| Dec 31, 2014 | 750,000.00 |
| Sep 30, 2014 | 750,000.00 |
| Mar 31, 2012 | 1,945.00 |